Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 926

1.

Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?

Li-Yu J, Clayburne G, Sieck M, Beutler A, Rull M, Eisner E, Schumacher HR Jr.

J Rheumatol. 2001 Mar;28(3):577-80.

PMID:
11296962
2.

Monosodium urate crystals in the knee joints of patients with asymptomatic nontophaceous gout.

Bomalaski JS, Lluberas G, Schumacher HR Jr.

Arthritis Rheum. 1986 Dec;29(12):1480-4.

PMID:
3801071
4.

Serum urate levels and gout flares: analysis from managed care data.

Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW.

J Clin Rheumatol. 2006 Apr;12(2):61-5.

PMID:
16601538
5.

Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.

Halpern R, Mody RR, Fuldeore MJ, Patel PA, Mikuls TR.

Curr Med Res Opin. 2009 Jul;25(7):1711-9. doi: 10.1185/03007990903017966.

PMID:
19485724
6.

Treating to target: a strategy to cure gout.

Perez-Ruiz F.

Rheumatology (Oxford). 2009 May;48 Suppl 2:ii9-ii14. doi: 10.1093/rheumatology/kep087. Review.

PMID:
19447780
7.

Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.

Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C.

J Rheumatol. 2009 Jun;36(6):1273-82. doi: 10.3899/jrheum.080814. Epub 2009 Mar 13.

PMID:
19286847
8.

[Clinical features of gout in a cohort of Italian patients].

Zampogna G, Andracco R, Parodi M, Cimmino MA.

Reumatismo. 2009 Jan-Mar;61(1):41-7. Italian.

9.

Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.

Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A.

Arthritis Rheum. 2002 Aug;47(4):356-60.

10.

Factors associated with acute gout attacks in normouricaemic gout patients receiving allopurinol: a retrospective study.

So MW, Lee SG, Kim YG, Lee CK, Yoo B.

Scand J Rheumatol. 2011 Nov;40(6):444-7. doi: 10.3109/03009742.2011.589033. Epub 2011 Sep 15.

PMID:
21916803
11.

What do I need to know about gout?

Becker MA, Ruoff GE.

J Fam Pract. 2010 Jun;59(6 Suppl):S1-8. Review.

PMID:
20544070
12.

A two-stage approach to the treatment of hyperuricemia in gout: the "dirty dish" hypothesis.

Perez-Ruiz F, Herrero-Beites AM, Carmona L.

Arthritis Rheum. 2011 Dec;63(12):4002-6. doi: 10.1002/art.30649.

13.

Gout--what are the treatment options?

Schlesinger N, Dalbeth N, Perez-Ruiz F.

Expert Opin Pharmacother. 2009 Jun;10(8):1319-28. doi: 10.1517/14656560902950742. Review.

PMID:
19463070
14.

Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved.

Thiele RG, Schlesinger N.

Rheumatol Int. 2010 Feb;30(4):495-503. doi: 10.1007/s00296-009-1002-8. Epub 2009 Jun 20.

PMID:
19543895
15.

Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study.

Perez-Ruiz F, Atxotegi J, Hernando I, Calabozo M, Nolla JM.

Arthritis Rheum. 2006 Oct 15;55(5):786-90.

16.

Diagnosis and treatment of gout in primary care.

Rakieh C, Conaghan PG.

Practitioner. 2011 Dec;255(1746):17-20, 2-3. Review.

PMID:
22272526
17.

The effect of control and self-medication of chronic gout in a developing country. Outcome after 10 years.

Darmawan J, Rasker JJ, Nuralim H.

J Rheumatol. 2003 Nov;30(11):2437-43.

PMID:
14677190
18.

Gout: an update.

Eggebeen AT.

Am Fam Physician. 2007 Sep 15;76(6):801-8. Review.

20.

Diagnosis and management of gout.

Pittman JR, Bross MH.

Am Fam Physician. 1999 Apr 1;59(7):1799-806, 1810. Review.

Supplemental Content

Support Center